Oligon is an emerging biotechnology company developing a novel class of multimodal RNA therapeutics.
Oligon has raised $14.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2025.
Oligon's investors include Fonds de solidarité FTQ, CTI Life Sciences Fund, Investissement Quebec.
Oligon is headquartered in Scottsdale, United States.
Oligon is an emerging biotechnology company developing a novel class of multimodal RNA therapeutics.
Oligon is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Oligon — Funding & Investors." VCBacked, September 23, 2025, https://www.vcbacked.co/company/oligon. Accessed August 7, 2026.
VCBacked. (2025). Oligon — Funding & Investors. Retrieved August 7, 2026, from https://www.vcbacked.co/company/oligon
{{cite web |title=Oligon — Funding & Investors |url=https://www.vcbacked.co/company/oligon |website=VCBacked |access-date=August 7, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated